The artificial pancreas — the automated closed-loop control of diabetes mellitus — made its first outpatient strides in 2011. In 2017, the results of long-term clinical trials on the artificial pancreas were published, the first hybrid commercial artificial pancreas system was approved and the artificial pancreas was tested under increasingly demanding conditions. Thus, artificial pancreas technology is here to stay.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hovorka, R. Closed-loop insulin delivery: from bench to clinical practice. Nat. Rev. Endocrinol. 7, 385–395 (2011).
Cefalu, W. T. & Tamborlane, W. V. The artificial pancreas: are we there yet? Diabetes Care 37, 1182–1183 (2014).
Kovatchev, B. P., Tamborlane, W. V., Cefalu, W. T. & Cobelli, C. The artificial pancreas in 2016: a digital treatment ecosystem for diabetes. Diabetes Care 39, 1123–1127 (2016).
Bergenstal, R. M. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316, 1407–1408 (2016).
Garg, S. K. et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol. Ther. 19, 155–163 (2017).
Bally, L. et al. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol. 5, 261–270 (2017).
Dassau, E. et al. 12-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin A1c and hypoglycemia. Diabetes Care http://dx.doi.org/10.2337/dc17-1188 (2017).
Dovc, K. et al. Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. Diabetologia 60, 2157–2167 (2017).
Breton, M. D. et al. Closed loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study. Diabetes Care http://dx.doi.org/10.2337/dc17-0883 (2017).
National Institutes of Health. Four pivotal NIH-funded artificial pancreas research efforts begin. NIH https://www.nih.gov/news-events/news-releases/four-pivotal-nih-funded-artificial-pancreas-research-efforts-begin (2017).
The author's work on closed-loop control is supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grants DP3 DK101055, RO1 DK 085623 and UC4 108483 – the International Diabetes Closed-Loop Trial, and by the University of Virginia's Strategic Investment in Type 1 Diabetes.
B.K. has received speaking engagements/honoraria from Dexcom and Sanofi; research support managed by the University of Virginia from Ascensia Diabetes Care, Dexcom, Roche Diagnostics and Tandem Diabetes Care; patent royalties managed by the University of Virginia from Johnson & Johnson and Sanofi; and is shareholder/board member of TypeZero Technologies, Inc.
About this article
Cite this article
Kovatchev, B. The year of transition from research to clinical practice. Nat Rev Endocrinol 14, 74–76 (2018). https://doi.org/10.1038/nrendo.2017.170
ACS Applied Polymer Materials (2020)
Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial
The Lancet Digital Health (2020)
Artificial Organs (2020)
TiO 2 Nanoflowers on Conducting Substrates Ameliorate Effective Transdifferentiation of Human Hepatic Progenitor Cells for Long‐Term Hyperglycemia Reversal in Diabetic Mice
Advanced Therapeutics (2020)
npj Digital Medicine (2019)